Your browser doesn't support javascript.
loading
Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours.
Ramundo, V; Del Prete, M; Marotta, V; Marciello, F; Camera, L; Napolitano, V; De Luca, L; Circelli, L; Colantuoni, V; Di Sarno, A; Carratù, A C; de Luca di Roseto, C; Colao, A; Faggiano, A.
Afiliación
  • Ramundo V; Department of Clinical Medicine and Surgery, "Federico II" University of Naples, Naples, Italy.
Clin Endocrinol (Oxf) ; 80(6): 850-5, 2014 Jun.
Article en En | MEDLINE | ID: mdl-24443791
BACKGROUND: Somatostatin analogues (SSA) represent one of the main therapeutic option in patients affected with functioning well-differentiated neuroendocrine tumours (NETs). There are no studies specifically focusing on NETs associated with Multiple Endocrine Neoplasia type 1 (MEN1). AIM: To evaluate the efficacy of the long-acting SSA octreotide in MEN1 patients with early-stage duodeno-pancreatic NETs. PATIENTS AND METHODS: Forty patients with MEN1 were retrospectively evaluated. Twenty patients with evidence of one or more MEN1-related duodeno-pancreatic NETs < 20 mm in size (age range 26-61 years) were treated with octreotide long-acting octreotide (LAR) as first-line therapy. Treatment duration ranged 12-75 months. At the baseline radiological evaluation, multiple duodeno-pancreatic NETs (range 1-8, size 3-18 mm) were detected. RESULTS: An objective tumour response was observed in 10%, stable disease in 80% and progression of disease in 10% of cases. In six patients with abnormally increased CgA, gastrin and/or insulin serum concentrations, a significant clinical and hormonal response occurred in 100% of cases and was stable along the time. CONCLUSIONS: Therapy with SSA is highly safe and effective in patients with early-stage MEN1 duodeno-pancreatic NETs, resulting in long-time suppression of tumour and hormonal activity and 10% objective response. This suggests to early start therapy with SSA in patients with MEN1-related NETs.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Octreótido / Tumores Neuroendocrinos / Neoplasia Endocrina Múltiple Tipo 1 Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Endocrinol (Oxf) Año: 2014 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Octreótido / Tumores Neuroendocrinos / Neoplasia Endocrina Múltiple Tipo 1 Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Endocrinol (Oxf) Año: 2014 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido